pan-HER-IN-2(Cat No.:I043710)is a selective inhibitor targeting the human epidermal growth factor receptor (HER) family, which includes HER1, HER2, HER3, and HER4. By inhibiting these receptors, pan-HER-IN-2 disrupts the signaling pathways that drive cell proliferation, survival, and migration, commonly implicated in cancer, especially breast and ovarian cancers. This pan-HER inhibitor has shown promise in preclinical studies by blocking receptor dimerization and downstream signaling. It holds potential for overcoming resistance to targeted therapies and may provide an effective treatment option for HER-driven malignancies, advancing cancer therapy research.